Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Key facts
- Where
- Mississauga, Richmond Hill, St. John's, and Toronto, CanadaSee the 4 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Source: NCT07213973, who can take part
Where in Canada
- Dermcare ClinicMississauga, CanadaTaking people
- York Dermatology CenterRichmond Hill, CanadaTaking people
- Skincare Studio Dermatology CentreSt. John's, CanadaTaking people
- The Hospital for Sick ChildrenToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07213973
- Record updated
- 9 October 2026
- Original description
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.Read full original descriptionShow less
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Inclusion: Aged ≥ 12 to < 18 years at the time of informed consent/assent signing; Body weight ≥ 30 kg at both screening and baseline visits; Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit; Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits; HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits; Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS); Agreement to use contraception; Willing and able to comply with the study protocol and procedures; Further inclusion criteria apply.
Exclusion: Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator; Laboratory values outside of the protocol-defined ranges; Presence of > 20 draining tunnels (fistulas) at either the screening or baseline visit; Women who are pregnant (or who are considering pregnancy) or breastfeeding; Further exclusion criteria apply.